LNWTC
UTHR icon

Laird Norton Wetherby Trust Company’s United Therapeutics UTHR Stock Holding History

Laird Norton Wetherby Trust Company’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$550K Buy
1,015
+12
+1% +$6.76K 0.01% 680
2026
Q1 		$595K Buy
1,003
+19
+2% +$9.46K 0.01% 638
2025
Q4 		$479K Buy
+984
New +$458K 0.01% 729

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Laird Norton Wetherby Trust Company's UTHR Position: Q2 2026 in Review

Laird Norton Wetherby Trust Company increased its United Therapeutics (UTHR) stake by 1.2% in Q2 2026, buying an estimated $6.76K and bringing the position to 1,015 shares worth $550K. The position accounts for 0.01% of the portfolio, ranked #680.

Laird Norton Wetherby Trust Company first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $595K in Q1 2026. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Laird Norton Wetherby Trust Company held 1,015 shares of United Therapeutics worth $550K as of Q2 2026.
  • Laird Norton Wetherby Trust Company bought 12 United Therapeutics shares in Q2 2026, an estimated $6.76K.
  • United Therapeutics made up 0.01% of Laird Norton Wetherby Trust Company's portfolio in Q2 2026, its #680 holding.
  • Laird Norton Wetherby Trust Company first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Laird Norton Wetherby Trust Company's United Therapeutics position peaked at $595K in Q1 2026.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Laird Norton Wetherby Trust Company's 13F filing for Q2 2026, filed 14 Aug 2026.